Active Clinical Trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. Learn more about the active studies conducted by Novartis including opportunities to get involved.

Showing 174 results
  • Sort by Sort ascending
  • Study title
  • Condition
  • Phase
  • Location
Study title Condition Phase Location

Specified Drug-use Surveillance of Fabhalta Capsules

Paroxysmal Nocturnal Hemoglobinuria Japan

Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS

Relapsing Multiple Sclerosis Phase3 United States

A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)

Healthy Volunteers, Pulmonary Arterial Hypertension Phase1, Phase2 United States

An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

Systemic Lupus Erythematosus, SLE Phase1 Spain

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

Sickle Cell Disease Phase3 United States

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

Amyotrophic Lateral Sclerosis (ALS) Phase2 United States

Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy (SMA) Greece
Ireland
Israel
Korea, Republic of
Poland
Portugal
Romania
Russian Federation
Taiwan
United States
View All

Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy

Atypical Hemolytic Uremic Syndrome Phase3 Austria
Brazil
China
Czechia
Greece
India
Japan
Korea, Republic of
Slovakia
Slovenia
Taiwan
United Kingdom
United States
View All

Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis

Moderate-to-severe Plaque Psoriasis Russian Federation

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

Relapsing Multiple Sclerosis Phase3 Argentina
Austria
Belgium
Bulgaria
Chile
China
Colombia
Croatia
Denmark
Georgia
Guatemala
Hong Kong
India
Ireland
Israel
Italy
Jordan
Latvia
Lebanon
Lithuania
Malaysia
Mexico
Netherlands
Poland
Saudi Arabia
Slovakia
Spain
Switzerland
Taiwan
United Arab Emirates
United Kingdom
United States
View All